Anticoagulants Global Market Report 2026

Anticoagulants are drugs used to prevent and treat blood clots in the heart and blood vessels and are also commonly referred to as blood thinners. They work by slowing down the body's clotting mechanism. Although called blood thinners, they do not actually thin the blood but instead prevent or reduce the formation of clots, also known as thrombi.

The primary drug classes of anticoagulants include Factor Xa inhibitors, heparin and LMWH, vitamin K antagonists, and others. Factor Xa inhibitors are anticoagulants that prevent clot formation by selectively and reversibly inhibiting the activity of clotting factor Xa. The various routes of administration include oral and injectable anticoagulants, which are distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies. Anticoagulants are used in the treatment of venous thromboembolism, atrial fibrillation or flutter, coronary artery disease, and other conditions, and are administered across settings including hospitals, home care, specialty centers, and others.

Tariffs have impacted the anticoagulants market by increasing costs of imported active pharmaceutical ingredients, finished formulations, and specialized manufacturing inputs. This has affected pricing and availability of factor Xa inhibitors, heparins, and novel oral anticoagulants, particularly in regions reliant on pharmaceutical imports such as Asia-Pacific and Latin America. Hospital pharmacies and retail channels face margin pressure due to elevated procurement costs. However, tariffs are also encouraging local API production, regional manufacturing investments, and supply chain diversification, supporting long-term market resilience.

The anticoagulants market research report is one of a series of new reports from The Business Research Company that provides anticoagulants market statistics, including anticoagulants industry global market size, regional shares, competitors with a anticoagulants market share, detailed anticoagulants market segments, market trends and opportunities, and any further data you may need to thrive in the anticoagulants industry. This anticoagulants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anticoagulants market size has grown rapidly in recent years. It will grow from $53.88 billion in 2025 to $60.42 billion in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to high prevalence of cardiovascular diseases, increasing incidence of venous thromboembolism, long-standing use of warfarin, growth in hospital-based treatments, rising awareness of stroke prevention.

The anticoagulants market size is expected to see rapid growth in the next few years. It will grow to $97.07 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to growing atrial fibrillation population, expanding use of factor Xa inhibitors, improved safety profiles of NOACs, increasing outpatient anticoagulation management, rising adoption in emerging markets. Major trends in the forecast period include rising adoption of direct oral anticoagulants, shift from injectable to oral therapies, increasing long-term anticoagulation therapy use, growing focus on patient compliance and safety, expanding use in preventive cardiovascular care.

The rising prevalence of cardiovascular diseases is a major factor fueling the growth of the anticoagulants market in the coming years. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels. They represent the leading cause of death globally, with low- and middle-income countries accounting for approximately three-quarters of all CVD-related deaths. Anticoagulation pharmacotherapy, particularly direct oral anticoagulants, is widely used to reduce the risk of thrombosis across various cardiovascular conditions. For example, in September 2025, according to the British Heart Foundation, a UK-based charity, more than 7.6 million people in the UK-including over 4 million men and more than 3.6 million women-were living with cardiovascular disease, and projections suggest that, driven by an aging population and improved survival rates, this number could increase by around 1 million by 2030 and by about 2 million by 2040. Consequently, the growing incidence of cardiovascular diseases is driving the expansion of the anticoagulants market.

Leading companies operating in the anticoagulants market are concentrating on the development of advanced solutions such as factor Xa inhibitor tests to address the rising demand for testing driven by the increased use of direct oral anticoagulants for stroke prevention and other serious cardiovascular conditions. Factor Xa inhibitor tests are diagnostic assessments designed to measure the efficacy and safety of anticoagulant drugs that selectively inhibit factor Xa, thereby preventing blood clot formation in various clinical scenarios. For example, in February 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based biotechnology company, introduced coagulation tests for apixaban, edoxaban, and rivaroxaban. These newly launched factor Xa inhibitor coagulation tests use Roche's innovative reagent cassette technology, delivering high-quality results and efficient sample processing while enabling standardization and automation to improve laboratory workflows. These tests play an important role in supporting clinical decision-making for patients using direct oral anticoagulants for stroke prevention, addressing the growing global need for reliable diagnostics in the management of serious conditions such as coronary artery disease and peripheral arterial disease.

In April 2025, Novartis, a Switzerland-based developer of innovative pharmaceuticals and biologics, acquired Anthos Therapeutics for up to $3.1 billion. Through this acquisition, Novartis intends to enhance its presence in the anticoagulant therapeutics market by progressing a late-stage Factor XI inhibitor with the potential to address major unmet needs in the treatment of thromboembolic diseases. Anthos Therapeutics is a US-based biopharmaceutical company focused on the development of monoclonal antibody-based anticoagulant therapies, including the Phase 3 investigational drug abelacimab for stroke prevention and cancer-associated thrombosis.

Major companies operating in the anticoagulants market are GlaxoSmithKline plc, Leo Pharma A/S, Amphastar Pharmaceuticals Inc., Bayer AG, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Mylan N.V., Pfizer Inc., Sanofi S.A., Apotex Inc., Aspen Pharmacare Holdings Limited, AstraZeneca plc, Bristol-Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson, Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Natco Pharma Limited, Novartis International AG, Portola Pharmaceuticals Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Torrent Pharmaceuticals Limited, and Zydus Cadila Healthcare Limited.

North America was the largest region in the anticoagulants market in 2025. The regions covered in the anticoagulants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the anticoagulants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anticoagulants market consists of sales of rivaroxaban, dabigatran, apixaban, and edoxaban. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anticoagulants Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses anticoagulants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anticoagulants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The anticoagulants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Class: Factor Xa Inhibitor; Heparin And LMWH; Vitamin K Antagonist; Other Drug Classes
• 2) By Route Of Administration: Oral Anticoagulant; Injectable Anticoagulant
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• 4) By Application: Venous Thromboembolism; Atrial Fibrillation Or Flutter; Coronary Artery Disease; Other Applications
• 5) By End User: Hospitals; Homecare; Specialty Centers; Other End-Users
• Subsegments:
• 1) By Factor Xa Inhibitor: Rivaroxaban; Apixaban; Edoxaban; Betrixaban
• 2) By Heparin And LMWH (Low Molecular Weight Heparin): Unfractionated Heparin; Enoxaparin; Dalteparin; Tinzaparin
• 3) By Vitamin K Antagonist: Warfarin; Acenocoumarol; Phenprocoumon
• 4) By Other Drug Classes: Direct Thrombin Inhibitors; Novel Oral Anticoagulants (NOACs)
• Companies Mentioned: GlaxoSmithKline plc; Leo Pharma A/S; Amphastar Pharmaceuticals Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Daiichi Sankyo Company Limited; Eisai Co. Ltd.; Mylan N.V.; Pfizer Inc.; Sanofi S.A.; Apotex Inc.; Aspen Pharmacare Holdings Limited; AstraZeneca plc; Bristol-Myers Squibb Company; Dr. Reddy's Laboratories Ltd.; Fresenius Kabi AG; Hikma Pharmaceuticals plc; Johnson & Johnson; Lupin Limited; Mitsubishi Tanabe Pharma Corporation; Natco Pharma Limited; Novartis International AG; Portola Pharmaceuticals Inc.; Strides Pharma Science Limited; Sun Pharmaceutical Industries Limited; Teva Pharmaceutical Industries Limited; Torrent Pharmaceuticals Limited; and Zydus Cadila Healthcare Limited.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.